Combating fibrosis in mdx mice with a novel antifibrosis drug - Halofuginone
| dc.contributor.author | Huebner, Kyla Danielle | |
| dc.contributor.examiningcommittee | Thliveris, James (Human Anatomy and Cell Science) Scott, Elliott (Oral Biology) | en |
| dc.contributor.supervisor | Anderson, Judith (Human Anatomy and Cell Science) | en |
| dc.date.accessioned | 2007-04-26T19:01:49Z | |
| dc.date.available | 2007-04-26T19:01:49Z | |
| dc.date.issued | 2007-04-26T19:01:49Z | |
| dc.degree.discipline | Human Anatomy and Cell Science | en_US |
| dc.degree.level | Master of Science (M.Sc.) | en_US |
| dc.description.abstract | The effects of the antifibrotic drug Halofuginone hydrobromide (Halo) on muscle function, regeneration and cardiorespiratory function were studied using mdx mice. It was hypothesized that Halo treatment would resolve pre-established fibrosis and prevent collagen deposits, improving muscle and cardio-respiratory function. Mice 8-9 mos were treated with saline or Halo for 5 (n = 4/group), 10 (n = 5/group) and 12 weeks (n = 4-5/group). Muscle strength and endurance, respiration and muscle susceptibility to damage were assessed. Tissues were collected from all mice. Additional mice were treated for 10 wks (3-4 wks n = 9-10/group; 8-9 mos n = 8-9/group) for echocardiography. Halo reduced fibrosis. As a consequence, there was muscle repair and damage was reduced. There were functional improvements and disease progression was slowed. There was resolution of pre-existing fibrosis and reduction of new collagen synthesis. This treatment could improve quality of life and lengthen the lifespan of DMD patients. | en |
| dc.description.note | May 2007 | en |
| dc.format.extent | 2310116 bytes | |
| dc.format.extent | 2310116 bytes | |
| dc.format.extent | 2310116 bytes | |
| dc.format.extent | 2310116 bytes | |
| dc.format.extent | 2310116 bytes | |
| dc.format.mimetype | application/octet-stream | |
| dc.format.mimetype | application/octet-stream | |
| dc.format.mimetype | application/octet-stream | |
| dc.format.mimetype | application/octet-stream | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.uri | http://hdl.handle.net/1993/329 | |
| dc.language.iso | eng | en_US |
| dc.rights | open access | en_US |
| dc.subject | Dystrophy | en |
| dc.subject | Fibrosis | en |
| dc.title | Combating fibrosis in mdx mice with a novel antifibrosis drug - Halofuginone | en |
| dc.type | master thesis | en_US |